Cardiac Complications, Earlier Treatment, and Initial Disease Severity in Kawasaki Disease

Joseph Y Abrams1, Ermias D Belay1, Ritei Uehara2

  • 1Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.

Insights

Early treatment for Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) is not linked to higher cardiac risks. Initial disease severity, not early IVIG, explains the observed associations in KD patients.

Area of Science:

  • Pediatrics
  • Immunology
  • Cardiology

Background:

  • Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
  • Concerns exist regarding potential cardiac complications associated with early treatment for KD.

Purpose of the Study:

  • To investigate whether higher observed risks of cardiac complications in early-treated KD patients are due to confounding by initial disease severity.
  • To clarify the true effect of early intravenous immunoglobulin (IVIG) treatment on cardiac outcomes in KD.

Main Methods:

  • Analysis of Japanese nationwide KD surveys (1997-2004) involving 48,310 patients.
  • Used receipt of additional IVIG or treatments as proxies for initial disease severity.
  • Employed logistic modeling and stratification to assess associations between early (days 1-4) vs. late (days 5-10) IVIG treatment and cardiac complications.

Main Results:

  • Unadjusted analysis showed higher risks of cardiac complications with earlier IVIG treatment.
  • Stratification by additional treatment and logistic modeling controlling for it removed this association.
  • Early IVIG treatment (days 1-4) demonstrated a protective effect against major cardiac complications (OR, 0.90; 95% CI, 0.80-1.00) after adjustment.

Conclusions:

  • Observed higher cardiac complication risks in early-treated KD patients are likely attributable to underlying disease severity, not the early treatment itself.
  • Early IVIG treatment remains a recommended and beneficial strategy for managing Kawasaki disease.
Abstract

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
647
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
574
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
673
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
422
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
782